Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Show more
Location: 2450 Holcombe Blvd, Houston, TX, 77021, United States | Website: https://markertherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
12.87M
52 Wk Range
$0.81 - $5.95
Previous Close
$0.99
Open
$0.99
Volume
167,009
Day Range
$0.95 - $1.02
Enterprise Value
2.41M
Cash
10.46M
Avg Qtr Burn
-2.721M
Insider Ownership
7.08%
Institutional Own.
26.37%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
MT-601 (Neldaleucel) Details Non-Hodgkin Lymphoma (NHL) | Phase 1 Data readout | |
MT-601 (Neldaleucel) + chemotherapy Details Pancreatic cancer | Phase 1 Initiation | |
MT-401-OTS Details Acute myeloid leukemia | Phase 1 Initiation | |
MT-401 Details Acute myeloid leukemia | Failed Discontinued |